Completed NA INTERVENTIONAL 1-arm NCT00890552

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Sponsor: Celgene Corporation

Interventions Dexamethasone Lenalidomide Melphalan

Updated 6 times since 2017 Last updated: Feb 1, 2017 Started: Apr 30, 2009 Primary completion: Aug 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00890552, this NA trial focuses on Amyloidosis and Leukemia and remains completed. Sponsored by Celgene Corporation, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
May 2017 — Jun 2018 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Completed NA

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States